Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PLX 
Protalix Biotherapeutics Inc (PLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: PLX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14
1 Year Target Price $14
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2.86% | Avg. Invested days 21 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 123.58M USD | Price to earnings Ratio 17.22 | 1Y Target Price 14 |
Price to earnings Ratio 17.22 | 1Y Target Price 14 | ||
Volume (30-day avg) 1 | Beta -0.21 | 52 Weeks Range 0.96 - 3.10 | Updated Date 08/29/2025 |
52 Weeks Range 0.96 - 3.10 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-14 | When - | Estimate 0.11 | Actual -0.04 |
Profitability
Profit Margin 10.13% | Operating Margin (TTM) 7.49% |
Management Effectiveness
Return on Assets (TTM) 6.05% | Return on Equity (TTM) 15.99% |
Valuation
Trailing PE 17.22 | Forward PE 28.17 | Enterprise Value 95535778 | Price to Sales(TTM) 2 |
Enterprise Value 95535778 | Price to Sales(TTM) 2 | ||
Enterprise Value to Revenue 1.54 | Enterprise Value to EBITDA 9.2 | Shares Outstanding 79732096 | Shares Floating 60755074 |
Shares Outstanding 79732096 | Shares Floating 60755074 | ||
Percent Insiders 10.54 | Percent Institutions 15.14 |
Upturn AI SWOT
Protalix Biotherapeutics Inc
Company Overview
History and Background
Protalix Biotherapeutics Inc. was founded in 1993 and is headquartered in Carmiel, Israel. It focuses on the development and commercialization of recombinant therapeutic proteins based on its plant cell-based expression system, ProCellEx.
Core Business Areas
- Therapeutic Protein Development: Development of complex therapeutic proteins for treating genetic disorders and other diseases using the ProCellEx platform.
- Commercialization of Elelyso: Commercialization of Elelyso (taliglucerase alfa) for the treatment of Gaucher disease.
- Pipeline Expansion: Expanding its pipeline with additional product candidates addressing unmet medical needs.
Leadership and Structure
The leadership team consists of experienced professionals in biotechnology and pharmaceuticals. The company has a typical organizational structure with departments for R&D, manufacturing, commercialization, and finance.
Top Products and Market Share
Key Offerings
- Elelyso (taliglucerase alfa): Elelyso is a recombinant enzyme replacement therapy for the treatment of Gaucher disease. Its market share fluctuates based on competition from other enzyme replacement therapies and novel therapies. Competitors include Sanofi Genzyme (Cerezyme and Cerdelga), and Takeda (VPRIV).
- Pegunigalsidase alfa: Pegunigalsidase alfa (PRX-102) is a novel investigational therapy for the treatment of Fabry disease. It is being developed in collaboration with Chiesi Farmaceutici S.p.A. Competitors include Amicus Therapeutics (Galafold), Sanofi Genzyme (Fabrazyme), and Takeda (Replagal).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high R&D costs, long development timelines, and intense competition. It is also influenced by regulatory approvals, reimbursement policies, and technological advancements.
Positioning
Protalix is positioned as a company with a unique plant cell-based expression system that offers advantages in terms of production efficiency and cost-effectiveness. The company focuses on niche markets with unmet medical needs.
Total Addressable Market (TAM)
The TAM for enzyme replacement therapies and Fabry disease treatments is significant, projected to be in the billions of dollars. Protalix's position within this TAM depends on the success of their clinical trials and the commercial acceptance of their products.
Upturn SWOT Analysis
Strengths
- Proprietary ProCellEx platform
- Approved product (Elelyso)
- Partnership with Chiesi
- Potential for cost-effective manufacturing
Weaknesses
- Limited financial resources
- Dependence on a few key products
- Competition from larger pharmaceutical companies
- Historical Revenue concentration with Elelyso
Opportunities
- Expansion of pipeline
- New partnerships
- Positive clinical trial results
- Market growth in rare diseases
Threats
- Competition from biosimilars
- Regulatory hurdles
- Clinical trial failures
- Economic downturn
Competitors and Market Share
Key Competitors
- SNY
- TAK
- FOLD
Competitive Landscape
Protalix's competitive advantage lies in its ProCellEx platform, but it faces strong competition from established pharmaceutical companies with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Protalix's historical growth has been influenced by product approvals, partnerships, and market competition.
Future Projections: Future growth is dependent on clinical trial outcomes, regulatory approvals, and commercial success of pipeline products. Analyst estimates vary.
Recent Initiatives: Recent initiatives include clinical trials for pegunigalsidase alfa, expansion of partnerships, and exploration of new therapeutic areas.
Summary
Protalix Biotherapeutics Inc. is a biotechnology company with a unique plant cell-based expression system. Elelyso and Pegunigalsidase alfa present potential avenues for growth. It faces challenges related to competition and limited financial resources. Positive clinical trial outcomes are crucial for its future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is based on estimates and may vary. Financial data is based on publicly available information and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Protalix Biotherapeutics Inc
Exchange NYSE MKT | Headquaters Hackensack, NJ, United States | ||
IPO Launch date 1998-05-15 | President, CEO & Director Mr. Dror Bashan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 213 | Website https://www.protalix.com |
Full time employees 213 | Website https://www.protalix.com | ||
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.